Tag: major depressive disorder industry size

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Major Depressive Disorder Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The global market for major depressive disorder treatments has experienced consistent expansion recently. Projections indicate a rise from $6.26 billion in 2025 to $6.44 billion by 2026, reflecting a compound annual growth rate of 2.9%. This upward trajectory during the past period is largely due to a rise in diagnosed depressive disorders, heightened public consciousness surrounding mental well-being, a greater accessibility of antidepressant pharmaceuticals, the broadening of mental health service provisions, and enhanced diagnostic criteria for mood-related conditions.

The market for major depressive disorder is poised for consistent expansion within the upcoming years, projected to reach $7.49 billion by 2030 with a CAGR of 3.9%. This anticipated growth trajectory is underpinned by several key factors, including the escalating mental health challenges stemming from lifestyle-related stress, the increasing integration of digital mental health solutions, a burgeoning need for tailored depression therapies, broader insurance accessibility for mental health services, and ongoing advancements in neuromodulation treatments. Furthermore, significant market trends to observe during this period encompass a greater embrace of combined therapeutic strategies, a heightened interest in non-invasive brain stimulation techniques, improved recognition and diagnosis rates for depression, the wider availability of telepsychiatry and remote mental healthcare, and a growing acceptance of innovative and swift-acting antidepressant medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Major Depressive Disorder Market Growth Momentum: Which Factors Are Influencing Demand?

Increased instances of addiction to drugs and alcohol are anticipated to be a primary catalyst for the expansion of the major depressive disorder market. Patterns of substance and alcohol consumption that are both excessive and detrimental, resulting in adverse effects on physical, psychological, and social well-being, are encompassed by the terms “substance abuse” and “alcohol abuse.” Major depressive disorder frequently coexists with these issues, creating a cycle where each condition exacerbates the other, thereby substantially elevating the potential for physical and mental health deterioration. Illustrating this point, data released in July 2024 by the Substance Abuse and Mental Health Services Administration, a U.S. governmental body focused on health and human services, revealed that 3.1 percent of individuals, amounting to 8.9 million people, engaged in opioid misuse during 2023, and a notable 21.8 percent of the population aged 12 and above consumed marijuana, establishing it as the most prevalent illicit substance. Furthermore, nicotine vaping among individuals aged 12 and over in the preceding month was reported by 9.4 percent, indicating a rise from the 8.3 percent recorded in 2022. Consequently, the increasing prevalence of substance and alcohol abuse is a significant factor contributing to the growth trajectory of the major depressive disorder market.

Major Depressive Disorder Market Segment Breakdown: Which Categories Generate The Most Revenue?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Major Depressive Disorder Market Trends Reshaping Industry Growth

Leading pharmaceutical entities participating in the major depressive disorder (MDD) space are prioritizing the creation of novel approaches, including prescription digital therapeutics (PDTs), to address the growing need for accessible, evidence-based psychotherapy, supplementary treatments for individuals with residual symptoms, and care models that leverage remote monitoring and data. PDTs represent software-based medical interventions that, once prescribed, deliver therapeutically validated content alongside tools for remote patient engagement, adherence tracking, and data collection for healthcare providers, offering a standardized, repeatable, and remotely supervised alternative to traditional medications or in-person therapy, particularly beneficial where access to specialized care is restricted. As an illustration, Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, introduced Rejoyn (initially designated CT-152) in April 2024, a PDT endorsed by the U.S. FDA as a complementary therapy for adults diagnosed with MDD currently undergoing pharmacotherapy, which involves a six-week, mobile-based regimen incorporating scientifically validated cognitive-emotional exercises (the Emotional Faces Memory Task/EFMT) and concise educational modules aimed at improving emotional regulation. This application operates through a prescribed channel where patients install and engage with scheduled sessions on their mobile devices, while clinicians oversee prescription and track patient progress, demonstrating efficacy in symptom reduction compared to a control group in the MIRAI randomized trial, distinguishing itself with a neuromodulatory framework targeting emotion-related neural circuits, personalized remote adherence prompts, and its classification as a regulated medical device.

Major Depressive Disorder Market Key Players And Strategic Industry Positioning

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Major Depressive Disorder Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Major Depressive Disorder Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The global market for major depressive disorder treatments has experienced consistent expansion recently. Projections indicate a rise from $6.26 billion in 2025 to $6.44 billion by 2026, reflecting a compound annual growth rate of 2.9%. This upward trajectory during the past period is largely due to a rise in diagnosed depressive disorders, heightened public consciousness surrounding mental well-being, a greater accessibility of antidepressant pharmaceuticals, the broadening of mental health service provisions, and enhanced diagnostic criteria for mood-related conditions.

The market for major depressive disorder is poised for consistent expansion within the upcoming years, projected to reach $7.49 billion by 2030 with a CAGR of 3.9%. This anticipated growth trajectory is underpinned by several key factors, including the escalating mental health challenges stemming from lifestyle-related stress, the increasing integration of digital mental health solutions, a burgeoning need for tailored depression therapies, broader insurance accessibility for mental health services, and ongoing advancements in neuromodulation treatments. Furthermore, significant market trends to observe during this period encompass a greater embrace of combined therapeutic strategies, a heightened interest in non-invasive brain stimulation techniques, improved recognition and diagnosis rates for depression, the wider availability of telepsychiatry and remote mental healthcare, and a growing acceptance of innovative and swift-acting antidepressant medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Major Depressive Disorder Market Growth Momentum: Which Factors Are Influencing Demand?

Increased instances of addiction to drugs and alcohol are anticipated to be a primary catalyst for the expansion of the major depressive disorder market. Patterns of substance and alcohol consumption that are both excessive and detrimental, resulting in adverse effects on physical, psychological, and social well-being, are encompassed by the terms “substance abuse” and “alcohol abuse.” Major depressive disorder frequently coexists with these issues, creating a cycle where each condition exacerbates the other, thereby substantially elevating the potential for physical and mental health deterioration. Illustrating this point, data released in July 2024 by the Substance Abuse and Mental Health Services Administration, a U.S. governmental body focused on health and human services, revealed that 3.1 percent of individuals, amounting to 8.9 million people, engaged in opioid misuse during 2023, and a notable 21.8 percent of the population aged 12 and above consumed marijuana, establishing it as the most prevalent illicit substance. Furthermore, nicotine vaping among individuals aged 12 and over in the preceding month was reported by 9.4 percent, indicating a rise from the 8.3 percent recorded in 2022. Consequently, the increasing prevalence of substance and alcohol abuse is a significant factor contributing to the growth trajectory of the major depressive disorder market.

Major Depressive Disorder Market Segment Breakdown: Which Categories Generate The Most Revenue?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Major Depressive Disorder Market Trends Reshaping Industry Growth

Leading pharmaceutical entities participating in the major depressive disorder (MDD) space are prioritizing the creation of novel approaches, including prescription digital therapeutics (PDTs), to address the growing need for accessible, evidence-based psychotherapy, supplementary treatments for individuals with residual symptoms, and care models that leverage remote monitoring and data. PDTs represent software-based medical interventions that, once prescribed, deliver therapeutically validated content alongside tools for remote patient engagement, adherence tracking, and data collection for healthcare providers, offering a standardized, repeatable, and remotely supervised alternative to traditional medications or in-person therapy, particularly beneficial where access to specialized care is restricted. As an illustration, Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, introduced Rejoyn (initially designated CT-152) in April 2024, a PDT endorsed by the U.S. FDA as a complementary therapy for adults diagnosed with MDD currently undergoing pharmacotherapy, which involves a six-week, mobile-based regimen incorporating scientifically validated cognitive-emotional exercises (the Emotional Faces Memory Task/EFMT) and concise educational modules aimed at improving emotional regulation. This application operates through a prescribed channel where patients install and engage with scheduled sessions on their mobile devices, while clinicians oversee prescription and track patient progress, demonstrating efficacy in symptom reduction compared to a control group in the MIRAI randomized trial, distinguishing itself with a neuromodulatory framework targeting emotion-related neural circuits, personalized remote adherence prompts, and its classification as a regulated medical device.

Major Depressive Disorder Market Key Players And Strategic Industry Positioning

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Major Depressive Disorder Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Major Depressive Disorder Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The global market for major depressive disorder treatments has experienced consistent expansion recently. Projections indicate a rise from $6.26 billion in 2025 to $6.44 billion by 2026, reflecting a compound annual growth rate of 2.9%. This upward trajectory during the past period is largely due to a rise in diagnosed depressive disorders, heightened public consciousness surrounding mental well-being, a greater accessibility of antidepressant pharmaceuticals, the broadening of mental health service provisions, and enhanced diagnostic criteria for mood-related conditions.

The market for major depressive disorder is poised for consistent expansion within the upcoming years, projected to reach $7.49 billion by 2030 with a CAGR of 3.9%. This anticipated growth trajectory is underpinned by several key factors, including the escalating mental health challenges stemming from lifestyle-related stress, the increasing integration of digital mental health solutions, a burgeoning need for tailored depression therapies, broader insurance accessibility for mental health services, and ongoing advancements in neuromodulation treatments. Furthermore, significant market trends to observe during this period encompass a greater embrace of combined therapeutic strategies, a heightened interest in non-invasive brain stimulation techniques, improved recognition and diagnosis rates for depression, the wider availability of telepsychiatry and remote mental healthcare, and a growing acceptance of innovative and swift-acting antidepressant medications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Major Depressive Disorder Market Growth Momentum: Which Factors Are Influencing Demand?

Increased instances of addiction to drugs and alcohol are anticipated to be a primary catalyst for the expansion of the major depressive disorder market. Patterns of substance and alcohol consumption that are both excessive and detrimental, resulting in adverse effects on physical, psychological, and social well-being, are encompassed by the terms “substance abuse” and “alcohol abuse.” Major depressive disorder frequently coexists with these issues, creating a cycle where each condition exacerbates the other, thereby substantially elevating the potential for physical and mental health deterioration. Illustrating this point, data released in July 2024 by the Substance Abuse and Mental Health Services Administration, a U.S. governmental body focused on health and human services, revealed that 3.1 percent of individuals, amounting to 8.9 million people, engaged in opioid misuse during 2023, and a notable 21.8 percent of the population aged 12 and above consumed marijuana, establishing it as the most prevalent illicit substance. Furthermore, nicotine vaping among individuals aged 12 and over in the preceding month was reported by 9.4 percent, indicating a rise from the 8.3 percent recorded in 2022. Consequently, the increasing prevalence of substance and alcohol abuse is a significant factor contributing to the growth trajectory of the major depressive disorder market.

Major Depressive Disorder Market Segment Breakdown: Which Categories Generate The Most Revenue?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Major Depressive Disorder Market Trends Reshaping Industry Growth

Leading pharmaceutical entities participating in the major depressive disorder (MDD) space are prioritizing the creation of novel approaches, including prescription digital therapeutics (PDTs), to address the growing need for accessible, evidence-based psychotherapy, supplementary treatments for individuals with residual symptoms, and care models that leverage remote monitoring and data. PDTs represent software-based medical interventions that, once prescribed, deliver therapeutically validated content alongside tools for remote patient engagement, adherence tracking, and data collection for healthcare providers, offering a standardized, repeatable, and remotely supervised alternative to traditional medications or in-person therapy, particularly beneficial where access to specialized care is restricted. As an illustration, Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, introduced Rejoyn (initially designated CT-152) in April 2024, a PDT endorsed by the U.S. FDA as a complementary therapy for adults diagnosed with MDD currently undergoing pharmacotherapy, which involves a six-week, mobile-based regimen incorporating scientifically validated cognitive-emotional exercises (the Emotional Faces Memory Task/EFMT) and concise educational modules aimed at improving emotional regulation. This application operates through a prescribed channel where patients install and engage with scheduled sessions on their mobile devices, while clinicians oversee prescription and track patient progress, demonstrating efficacy in symptom reduction compared to a control group in the MIRAI randomized trial, distinguishing itself with a neuromodulatory framework targeting emotion-related neural circuits, personalized remote adherence prompts, and its classification as a regulated medical device.

Major Depressive Disorder Market Key Players And Strategic Industry Positioning

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Major Depressive Disorder Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Major Depressive Disorder Market?

The major depressive disorder market size has shown steady growth in recent years. It is projected to increase from $6.26 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 2.9%. The expansion observed during the historic period can be linked to factors such as an escalating prevalence of depressive disorders, increasing societal recognition of mental health issues, enhanced availability of antidepressant medications, the broadening of psychiatric care infrastructure, and refined diagnostic guidelines for mood disorders.

The market for major depressive disorder is anticipated to experience consistent expansion over the upcoming years. By 2030, this market is projected to reach $7.49 billion, demonstrating a compound annual growth rate (CAGR) of 3.9%. This anticipated growth throughout the forecast period stems from factors such as an escalating mental health burden linked to lifestyle stress, wider embrace of digital mental health platforms, increased call for tailored depression treatments, broader insurance coverage for mental health services, and ongoing advancements in neuromodulation therapies. Key trends during this period are expected to encompass the increasing use of combination therapy strategies, a heightened need for non-invasive brain stimulation interventions, improved awareness and detection of depression, the expansion of telepsychiatry and remote mental health provisions, and a growing acceptance of innovative and fast-acting antidepressants.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Which Significant Factors Are Encouraging Growth In The Major Depressive Disorder Market?

The major depressive disorder market is anticipated to expand due to an increase in cases of substance and alcohol abuse. These terms characterize patterns of excessive and detrimental consumption of various substances, including alcohol, which can result in adverse physical, psychological, and social outcomes. This abuse frequently occurs alongside major depressive disorder, with both conditions often exacerbating each other and substantially elevating the danger of physical and mental damage. For example, in July 2024, a survey from the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, indicated that 3.1% of people (8.9 million) engaged in opioid misuse in 2023, and 21.8% of individuals aged 12 or older used marijuana, establishing it as the most widely used illicit drug. Furthermore, 9.4% of individuals aged 12 or older had vaped nicotine in the preceding month, an increase from 8.3% recorded in 2022. Consequently, the growing number of substance and alcohol abuse incidents is propelling the major depressive disorder market.

How Are Different Segment Groups Identified Within The Major Depressive Disorder Market?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Which Trends Are Expected To Shape The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder (MDD) market are prioritizing the development of innovative solutions, such as prescription digital therapeutics (PDTs), to address the increasing need for accessible, evidence-based psychotherapy, supplementary treatments for those with partial responses, and remote, data-driven care options. Prescription digital therapeutics are software-as-medical-device interventions administered via prescription, integrating clinically validated therapeutic content, remote engagement and adherence tools, and data capture capabilities for clinicians; distinct from traditional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can complement pharmacotherapy or fill service gaps where provider access is limited. For example, in April 2024, Japan-based Otsuka Pharmaceutical Co., in collaboration with Click Therapeutics, launched Rejoyn (developed as CT-152), a prescription digital therapeutic authorized by the U.S. FDA as an adjunctive treatment for adults with MDD who are already receiving antidepressant medication. Rejoyn is a six-week, smartphone-delivered program built around clinically validated cognitive-emotional brain-training exercises (the Emotional Faces Memory Task/EFMT) and concise therapeutic lessons designed to improve the cognitive control of emotion. The application operates through prescribed delivery, allowing patients to download and complete scheduled sessions on their smartphones while clinicians prescribe and monitor usage, and it was evaluated in the MIRAI randomised, sham-controlled trial, which demonstrated symptom improvement compared to the control group. Its distinguishing characteristics include its neuromodulatory design aimed at neural networks involved in emotion processing, remote, personalized reminders to enhance adherence, and its regulatory clearance as a medical device rather than a general wellness application.

Who Are The Key Market Participants In The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Access The Complete Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Geographic Region Represents The Largest Major Depressive Disorder Market Share?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Major Depressive Disorder Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2026, By The Business Research Company

E Pharmacy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/e-pharmacy-global-market-report

Digital Pharmacy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-pharmacy-global-market-report

Pharmacy Management System Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-management-system-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Major Depressive Disorder Market Be By 2030 Compared To Its 2026 Market Size?

The major depressive disorder market has experienced consistent expansion in recent years. This market is projected to grow from $6.26 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 2.9%. Historically, this growth can be attributed to the increasing prevalence of depressive disorders, growing societal awareness of mental health issues, wider availability of antidepressant medications, the expansion of psychiatric care infrastructure, and improved diagnostic guidelines for mood disorders.

The major depressive disorder market is projected to experience consistent expansion over the upcoming years, with its size anticipated to reach $7.49 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.9%. This growth during the forecast period is attributable to an escalating mental health burden resulting from lifestyle stress, the increasing uptake of digital mental health platforms, a rising demand for personalized depression treatments, broader insurance coverage for mental health care, and sustained innovation in neuromodulation therapies. Noteworthy trends in the forecast timeframe include the growing adoption of combination therapy approaches, an increasing preference for non-invasive brain stimulation treatments, enhanced awareness and diagnosis of depression, the expansion of telepsychiatry and remote mental health care, and greater acceptance of novel and rapid-acting antidepressants.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Primary Drivers Are Shaping The Major Depressive Disorder Market?

The increasing prevalence of substance and alcohol abuse is anticipated to fuel the expansion of the major depressive disorder market. Substance and alcohol abuse refers to patterns of detrimental and excessive consumption of various substances, including alcohol, which can result in adverse physical, psychological, and social repercussions. These conditions frequently co-exist with major depressive disorder, with each tending to exacerbate the other, thereby considerably elevating the likelihood of both physical and mental detriment. For example, a survey released in July 2024 by the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, reported that 3.1% of people (8.9 million) misused opioids in 2023. Additionally, 21.8% of individuals aged 12 or older utilized marijuana, establishing it as the most frequently consumed illicit drug. Furthermore, 9.4% of individuals aged 12 or older engaged in nicotine vaping in the preceding month, an increase from 8.3% recorded in 2022. Consequently, the escalating incidence of substance and alcohol abuse is propelling the growth of the major depressive disorder market.

How Are Segments Identified Within The Major Depressive Disorder Market Segment Framework?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5)

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) By Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) By Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) By Other Treatments: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

What Trends Are Affecting The Growth Of The Major Depressive Disorder Market?

Prominent companies operating within the major depressive disorder (MDD) market are concentrating their efforts on developing innovative solutions, such as prescription digital therapeutics (PDTs), to address the escalating demand for scalable access to evidence-based psychotherapy, adjunctive treatments for partial responders, and remote, measurement-driven care pathways. Prescription digital therapeutics (PDTs) are defined as software-as-medical-device interventions delivered via prescription, which integrate clinically validated therapeutic content, tools for remote engagement and adherence, and data capture capabilities for clinicians; in contrast to traditional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can either complement pharmacotherapy or fill gaps in provider access where limited. For example, in April 2024, Otsuka Pharmaceutical Co., a Japan-based pharmaceutical company, collaborated with Click Therapeutics to launch Rejoyn (developed as CT-152), a prescription digital therapeutic authorized by the U.S. FDA for use as an adjunctive treatment for adults with MDD who are concurrently on antidepressant medication. Rejoyn constitutes a six-week, smartphone-delivered program structured around clinically validated cognitive-emotional brain-training exercises (specifically, the Emotional Faces Memory Task/EFMT) and brief therapeutic lessons designed to enhance the cognitive control of emotion. The application operates through prescribed delivery, where patients download and complete scheduled sessions on their smartphone, while clinicians prescribe and monitor usage, and its efficacy was examined in the MIRAI randomized, sham-controlled trial, which demonstrated symptom improvement compared to the control. Its distinctive characteristics include its neuromodulatory design, intended to target neural networks implicated in emotion processing, personalized remote reminders to boost adherence, and regulatory clearance as a medical device rather than a wellness app.

Who Are The Companies Competing Within The Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Get The Full Major Depressive Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Region Is The Largest In The Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Major Depressive Disorder Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2026, By The Business Research Company

E Pharmacy Market Report 2026

https://www.thebusinessresearchcompany.com/report/e-pharmacy-global-market-report

Digital Pharmacy Market Report

https://www.thebusinessresearchcompany.com/report/digital-pharmacy-global-market-report

Pharmacy Management System Market Report

https://www.thebusinessresearchcompany.com/report/pharmacy-management-system-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model